<DOC>
	<DOCNO>NCT00053326</DOCNO>
	<brief_summary>This phase II trial study well fenretinide work treat child recurrent resistant neuroblastoma . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Fenretinide Treating Children With Recurrent Resistant Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Determine response rate pediatric patient recurrent resistant high-risk neuroblastoma treat fenretinide . Determine toxic effect drug patient . Determine proportion patient disease detect bone marrow immunocytology , clear evidence disease treatment drug . Determine minimal residual disease response marrow meta-iodobenzylguanidine ( MIBG ) I 123 scan patient treat drug . OUTLINE : Patients stratify accord presence measurable disease CT scan/MRI ( yes v ) . A third stratum patient tumor cell bone marrow immunocytology enrol evaluated response . Patients receive oral fenretinide 3 time daily ( 2 time daily 18 year age ) day 1-7 . Treatment repeat every 3 week 30 course absence disease progression unacceptable toxicity . Patients stratum III fail achieve complete response 8 course therapy remove study . Patients follow monthly blood count visual acuity stable normalize every 6 month 2 year annually 3 year . PROJECTED ACCRUAL : A total 70 patient ( 25 stratum I II , 20 stratum III ) accrue study within 1-2 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Diagnosis recurrent resistant/refractory highrisk neuroblastoma one following : Histological confirmation Demonstration tumor cell bone marrow increase urinary catecholamine Stratum I : At least 1 unidimensionally measurable lesion* At least 20 mm MRI and/or CT scan OR least 10 mm spiral CT scan Stratum II : Meets one follow criterion : At least 1 site positive uptake metaiodobenzylguanidine ( MIBG ) I 123 scan Tumor bilateral bone marrow aspirate/biopsy routine morphology ( NSE stain ) Stratum III : At least 5 tumor cells/10^6 mononuclear cell bone marrow immunocytology ( 2 successive bone marrow perform 1 day 4 week apart ) Patients first response ( i.e. , patient persistent tumor end frontline therapy , never disease relapse progression ) must histological* morphological ( bone marrow ) confirmation** viable tumor CT scan , MRI , MIBG scan completion myeloablative therapy ( stratum I II ) No catecholamine elevation Performance status 02 At least 2 month Hemoglobin great 7.5 g/dL ( transfusion allow ) Bilirubin great 1.5 time normal SGPT SGOT less 2.5 time normal Creatinine normal age No hematuria proteinuria great 1+ urinalysis Calcium le 11.6 mg/dL Triglycerides le 300 mg/dL Not pregnant Negative pregnancy test Fertile patient must use effective contraception No seizure disorder unless anticonvulsant well control No skin toxicity great grade 1 Must able consume entire intact study capsule dosage prescribe body surface area Recovered prior immunotherapy At least 7 day since prior anticancer biologic therapy At least 2 day since prior growth factor Prior autologous stem cell transplantation allow No prior allogeneic stem cell transplantation No concurrent immunomodulating agent At least 2 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) recover No concurrent anticancer chemotherapy No concurrent steroid Recovered prior radiotherapy At least 4 week since prior radiotherapy target lesion Prior radiotherapy non target lesion allow No concurrent radiotherapy sole measurable lesion symptom relief Concurrent palliative radiotherapy non target localize painful lesion allow Prior tretinoin isotretinoin allow At least 2 week since prior retinoids No prior fenretinide No concurrent supplemental oral IV vitamin A , ascorbic acid , vitamin E ( except contain routine total parenteral nutrition [ TPN ] vitamin supplement ) No concurrent drug suspect cause pseudotumor cerebri ( e.g. , tetracycline , nalidixic acid , nitrofurantoin , phenytoin , sulfonamide , lithium , amiodarone , vitamin A [ except part routine TPN supplement ] ) No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>